Metabolic diseases now drive up to a third of pediatric liver transplants -- this review maps the terrain.
Roshni Vara and Nedim Hadzic
This review traces how liver transplantation has become an established, sometimes curative treatment for inherited metabolic diseases in children, now accounting for roughly a quarter to a third of pediatric transplants. It discusses which conditions benefit most, the historical evolution of outcomes, and current debates around timing and patient selection. The authors frame ongoing challenges around expanding indications and intervening earlier in the disease course.
- The question: When is replacing a child's liver the right way to treat a metabolic disease?
- The study: This review traces how liver transplantation became an established, and sometimes curative, treatment for inherited metabolic diseases in children.
- The finding: Today, these conditions account for roughly a quarter to a third of all pediatric liver transplants.
- The nuance: The authors discuss which conditions benefit most, how outcomes have evolved over the decades, and current debates around timing and patient selection.
Takeaway: transplant can cure some metabolic diseases, so expanding indications and intervening earlier are the key challenges ahead.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.